General
Preferred name
TRIAMCINOLONE
Synonyms
Fluoxyprednisolone ()
Aristocort ()
Rodinolone ()
Cingal-triamcinolone ()
triamcinolone, Allergan ()
Volon ()
Kenacort ()
NSC-13397 ()
Delphicort ()
Triamcinolona ()
P&D ID
PD002598
CAS
124-94-7
Tags
available
drug
Approved by
FDA
First approval
1957
Drug indication
Airway obstruction
Allergic rhinitis
Drug Status
vet_approved
approved
withdrawn
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Triamcinolone is a synthetic glucocorticoid. The approved drug is often administered in the formulation .
PRICE
29
DESCRIPTION
Triamcinolone is a long-acting corticosteroid with anti-inflammatory, anti-oedematous, anti-proliferative, anti-angiogenetic, immunomodulatory and neuroprotective effects through binding to glucocorticoid receptors. Triamcinolone can relieve several dermatitis, immune diseases and ocular diseases[1][2].
DESCRIPTION
Triamcinolone is a synthetic glucocorticoid anti-inflammatory drug. The approved drug is often administered in the formulation . Hexacetonide, furetonide and benetonide forms are also used in the clinic, and have individual INNs.
(GtoPdb)
DESCRIPTION
Synthetic glucocorticoid agonist; inducer of gene expression and apoptosis
(LOPAC library)
DESCRIPTION
Triamcinolone (Aristocort) is a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. Upon cell entry, triamcinolone binds to and activates the glucocorticoid receptor, which leads to translocation of the ligand-receptor complex to the nucleus and induces expression of glucocorticoid-responsive genes such as lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both mediators of inflammation. In addition, pro-inflammatory cytokine production, including interleukin (IL)-1and IL-6, and the activation of cytotoxic T-lymphocytes is also inhibited. T-cells are prevented from making IL-2 and proliferating. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis through increasing Ikappa-B expression and curtailing activation of nuclear factor (NF)kappa-B.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
22
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
Natural product-based probes and drugs
NURSA ligand set
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
38
Molecular Weight
394.18
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
4
Rotatable Bonds
2
Ring Count
4
Aromatic Ring Count
0
cLogP
0.62
TPSA
115.06
Fraction CSP3
0.71
Chiral centers
8.0
Largest ring
6.0
QED
0.55
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
Glucocorticoid
Target
COX
Glucocorticoid Receptor
NR3C1
Interleukin Related
Indication
corticosteroid-responsive dermatoses
MOA
Glucocorticoid Receptor agonist
ATC
R03BA06
A01AC01
D07AB09
H02AB08
D07XB02
R01AD11
S01BA05
C05AA12
Biosynthetic Origin
Terpenoid (Steroid)
Therapeutic Indication
Antiarthritic
Therapeutic Class
Antiinflammatory
Antiinflammatory Agents
Pathway
Endocrinology/Hormones
Immunology/Inflammation
Neuroscience
Vitamin D Related/Nuclear Receptor
Source data
